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Connexins are a large family of proteins that form gap junction
channels allowing exchange of ions and small metabolites between
neighboring cells. They have been implicated in pathological pro-
cesses such as tumourigenesis in which they may act as tumour
suppressors. A polymorphism in the human connexin37 (Cx37)
gene (C1019T), resulting in a non-conservative amino acid change
in the regulatory C-terminus (CT) of the Cx37 protein (P319S)
has been suggested to be implicated in predisposition to angiosar-
comas. In this study, we have used communication-deficient HeLa
and SK-HEP-1 cells transfected with Cx37-319S, Cx37-319P or
empty vector. We showed that the expression of Cx37-319P lim-
ited proliferation of HeLa and SK-HEP-1 cells, whereas Cx37-
319S expression was without effect. Using an in vitro kinase assay,
we demonstrated phosphorylation of Cx37 CT by glycogen
synthase kinase-3 (GSK-3), a kinase known to be implicated in
cell proliferation and cancer. GSK-3-induced phosphorylation
was associated with reduced gap junctional intercellular commu-
nication (GJIC) as measured by microinjection of the tracer neu-
robiotin. Inhibition of GSK-3 by LiCl or SB415286 reduced
phosphorylation of Cx37-319P and increased GJIC. This latter
effect on GJIC involved the beta and not the alpha isoform of
GSK-3. In contrast, GSK-3 inhibitors were without effect on
HeLa cells expressing Cx37-319S. In conclusion, our data indicate
functional effects of the Cx37 C1019T polymorphism on GJIC
that might contribute to tumour cell growth.
Introduction
Gap junctional intercellular communication (GJIC) is essential to
maintain tissue homeostasis by transferring second messengers and
small metabolites between adjacent cells (1–3). Gap junction chan-
nels are oligomeric assemblies of connexins (Cx), members of a large
family of related proteins. Six connexins assemble into a hemichannel
or connexon, and a complete gap junction channel is formed by the
docking with a hemichannel of the neighboring cell. Functional re-
placement of one connexin gene with another revealed that cellular
homeostasis depends on types of connexin expressed (4). This implies
that the specific trafficking, permeability as well as interaction with
transduction networks of each connexin type is contributing to tissue
response (5).
GJIC is impaired in cancer tissues, which is generally considered to
contribute to aberrant growth of tumour cells (6,7). The lack of GJIC
among cancer cells may be the consequence of two separate phenom-
ena, i.e. a lack of expression or an aberrant localization of the con-
nexins (8–10). Interestingly, transfection of connexin genes in GJIC-
deficient tumour cells restores normal cell growth in vitro and in vivo
(6,11–15). These tumour-suppressive actions of connexin genes seem,
however, specific for the type of connexins and cells studied (6,7).
Because many tumour suppressor genes are mutated in cancer, the
occurrence of connexin gene mutations has been studied in various
types of tumours (16). Several studies have focused on Cx37 after an
initial report identifying tumour-associated antigenic peptides from
two mouse Lewis lung carcinoma cell lines (3LL and CMT) that
showed a strong sequence homology to (mutated) Cx37 protein
(17). Although DNA from these cell lines did not harbour the pro-
posed Cx37 mutations (18), other mutations were detected in this gene
in hepatic angiosarcomas from rats treated with vinyl chloride (19).
Moreover, immunohistochemical analysis in these angiosarcomas
failed to detect Cx37 at cell-to-cell contacts, whereas it was readily
observable in endothelial cells of normal liver.
A polymorphism in the human Cx37 gene (C1019T), resulting in
a non-conservative amino acid change (P319S) in the regulatory
C-terminus (CT) of the Cx37 protein, has been proposed as prognostic
marker for coronary artery disease and myocardial infarction (see
refs. for reviews 20,21). Using atherosclerosis-susceptible mice and
transfected mononuclear cells, we have previously demonstrated that
polymorphic Cx37 channels may function as prognostic markers for
atherosclerosis (22,23). The Cx37 C1019T polymorphism has also
been investigated in patients with hepatic angiosarcomas (24). These
rare malignant neoplasms arise from vascular endothelial cells and
have been linked to exposure to chemicals such as vinyl chloride or
Thorotrast (25,26). Although the authors suggested a tendency towards
over-representation of the 1019T allele, coding for Cx37-319S, in pa-
tients with vinyl chloride-induced tumours, this observation remained
inconclusive due to the very small sample number.
In the present study, we have compared cell proliferation between
communication-deficient cells (HeLa and SK-HEP-1) and cells stably
expressing similar levels of Cx37-319S and Cx37-319P. Our results
show decreased proliferation of cells expressing Cx37-319P. This re-
duced proliferation is not due to differences in cell adhesion or cell
death between the clones. Moreover, we have identified a unique site
in Cx37-319P for phosphorylation by glycogen synthase kinase 3
(GSK-3), a Ser/Thr kinase that is implicated in multiple cellular pro-
cesses and pathologies, including cell proliferation and cancer (re-
viewed in refs. 27,28). Finally, we show that inhibition of GSK-3b
equilibrates GJIC between Cx37-319S- and Cx37-319P-expressing
HeLa cells. Overall, our data indicate functional effects of the Cx37
C1019T polymorphism on GJIC that might contribute to tumour cell
growth.
Materials and methods
Cell cultures
Human HeLa cells (#CCL-2; American Type Culture Collection, Manassas,
UA) and human SK-HEP-1 cells (#HTB-52; American Type Culture Collec-
tion) were transfected with plasmids coding for human Cx37 polymorphisms
as described previously (23). The transfected human cell lines expressing
Cx37-319P, Cx37-319S or empty vector (EV) pIRES2-eGFP were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (FBS), 50 U/ml penicillin and 50 lg/ml streptomycin (Gibco BRL,
Basel, Switzerland). Transfected cells were under continuous selection pres-
sure with 300 lg/ml G418 (Gibco BRL) for HeLa cells and 500 lg/ml G418 for
SK-HEP-1 cells.
Cell proliferation assay
Cell proliferation was evaluated by two methods: one determining the number
of adherent cells only and another accounting for adherent and non-adherent
cells. For the first method, 5000 HeLa cells from each clone were inoculated in
Abbreviations: ATP, adenosine triphosphate; CT, C-terminus; DMSO, di-
methyl sulfoxide; EV, empty vector; FBS, fetal bovine serum; GJIC, gap
junctional intercellular communication; GSK-3, glycogen synthase kinase-3;
NS, not significant; SDS, sodium dodecyl sulphate; SiRNA, small interfering
RNA.
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triplicate into 96-well microtiter plate and kept in regular medium at 37C to
permit their adhesion. When adhesion was complete, medium was removed
and HeLa cells were maintained overnight in culture in medium without FBS
(Dulbecco’s modified Eagle’s medium supplemented with 5% bovine serum
albumin). To evaluate proliferation, HeLa cells were cultured for 48 h in
regular medium with FBS. At the end of this 2 day period, cells were stained
for 10 min with 0.1% crystal violet in 20% methanol (prepared in water) after
which the unbound dye was removed in tap water and the plate was air-dried
(29). The bound dye was solubilized in 2% sodium dodecyl sulphate (SDS)
and the absorbance of the samples was measured at 570 nm with a spectro-
photometer. Cell number was calculated using calibration curves made for
each clone.
For the second method, 5000 HeLa cells and 10 000 SK-HEP-1 cells of each
clone were grown as described above. At the end of the 2 day period, cell
proliferation was evaluated by using ‘CellTiter 96 Aqueous One Solution Cell
Proliferation Assay’ (Promega AG, Dubendorf, Switzerland). For this assay,
solution containing tetrazolium compound was added in each well for 90 min
at 37C. Viable cells (adherent and non-adherent cells) reduced the tetrazo-
lium compound and absorbance was read at 490 nm (T48). Results obtained
from HeLa and SK-HEP-1 cells transfected with Cx37-319P were expressed
in fold increase of cells transfected with Cx37-319S. To verify that initial
number of cells was similar between the two clones after overnight culture in
medium without FBS (T0), quantification of adherent cells was performed by
replacing culture medium by fresh medium and then adding tetrazolium
compound. Proliferation of HeLa cells was also quantified in presence of
50 U/ml apyrase or 200 lM adenosine triphosphate (ATP) (Sigma–Aldrich,
Buchs, Switzerland) (22). In addition, HeLa and SK-HEP-1 transfectants
were cultured in parallel dishes to verify equal Cx37 expression.
Cell death analysis
Death of HeLa cells after 2 days in culture was analysed by different methods.
First, the number of dead cells in culture dish supernatant was determined with
Trypan blue. Secondly, uncleaved and cleaved caspase-3 expression was eval-
uated by western blot. Finally, cell death was analysed by Fluorescence Activated
Cell Sorting. For this purpose, HeLa cells were incubated with phycoerythrin
Annexin V and 7-aminoactinomycin D for 30 min in the dark (PE Annexin V
Apoptosis Detection Kit I; BD Biosciences, Allschwill, Switzerland).
Protein extraction and western blotting
Proteins were extracted from transfected HeLa or SK-HEP-1 cells in mod-
ified RIPA buffer as described previously (23). Western blotting was per-
formed using antibodies against Cx37 (Alpha Diagnostics, VWR, Dietikon,
Switzerland), uncleaved and cleaved Caspase-3 (Cell Signaling Technology,
Allschwill, Switzerland), phospho-GSK-3b (Ser9) (Cell Signaling Technol-
ogy, Allschwill, Switzerland), total-GSK-3b (Cell Signaling Technology,
Allschwill, Switzerland), phospho-GSK-3a (Ser21) (Cell Signaling Technol-
ogy, Allschwill, Switzerland), total-GSK-3a (Cell Signaling Technology,
Allschwill, Switzerland), phospho-b-catenin (Ser33/Ser37/Thr41) (Cell Sig-
naling Technology, Allschwill, Switzerland), total-b-catenin (Cell Signal-
ing) and Glyceraldehyde 3-phosphate dehydrogenase (Chemicon, Basel,
Switzerland).
Prediction of phosphorylation sites and associated kinases in Cx37-319S and
Cx37-319P
The prediction of phosphorylated amino acids was performed with the NetPhos
2.0 Server and of the kinases involved with the NetPhosK 1.0 server (30).
Prediction analysis was done with evolutionary stable sites and with a threshold
of 0.5.
Production and purification of recombinant CT of Cx37-319S and Cx37-319P
Production of the CT tail of Cx37-319S and Cx37-319P (Cx37CT-319S and
Cx37CT-319P) was performed using methods described previously (31,32).
Cx37CT-319P was produced in BL-21 competent cells by introducing human
complementary DNA into pGEX-6P-2 plasmids (Amersham, Glattbrugg,
Switzerland). The resultant Glutathion-S-transferase-fusion protein was cleaved
to obtain amino acids 233–333 of human Cx37 (Cx37CT-319P). The Cx37CT-
319S clone was produced using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, Santa Clara, CA) on the Cx37CT-319P pGEX-6P-2 plasmid. The
following primers were used: forward, GAATGGCCAAAAATCCCCAAGTC-
GTC and reverse, GACGACTTGGGGATTTTTGGCCATTC. For the two
Cx37CT peptides, protein concentration was measured with the Bio-Rad DC
Protein Assay and purity was assessed by SDS–polyacrylamide gel electropho-
resis and Coomassie staining.
In vitro kinase assay
Phosphorylation of the CT tail of Cx37-319S and Cx37-319P by GSK-3b was
tested by an in vitro kinase assay in the presence of an active recombinant
GSK-3b. Cx37CT-319S and Cx37CT-319P were incubated with 1 lg of active
recombinant GSK-3b (Biovision, Mountain View, CA) for 30 min at 30C in
kinase buffer [25 mM Tris–HCl (pH 7.5), 5 mM b-glycerophosphate, 12 mM
MgCl2, 2 mM dithiothreitol, 1 mM sodium orthovanadate and a cocktail of
proteases inhibitors (Roche, Basel, Switzerland)] supplemented with 200 lM
ATP (Sigma–Aldrich) and 10 lCi [c-32P]ATP. The reaction was stopped by
adding SDS buffer. Samples were heated at 95C for 10 min, followed by
electrophoresis on a 15% polyacrylamide gel. The gels were stained with
Coomassie blue, dried and exposed overnight on a hyperfilm MP (Amersham).
Signals were quantified using NIH AutoExtractor 1.51 software.
The kinase assays were performed in presence of vehicle [H2O or dimethyl
sulfoxide (DMSO)] or GSK-3 inhibitors [10 mM LiCl and 50 lM SB415286
(Sigma–Aldrich)]. Optimal doses of GSK-3 inhibitors were determined in
HeLa cells using different concentrations of LiCl (0–40 mM) and SB415286
(0–100 lM). The efficacy of inhibition of GSK-3 activity was evaluated by
western blot by using antibodies against phospho-GSK-3b, total-GSK-3b,
phospho-GSK-3a and total-GSK-3a for LiCl treatment and with antibodies
against phospho-b-catenin and total-b-catenin for SB415286 treatment.
Immunofluorescence
Transfected HeLa cells were grown to confluence onto coverslips and fixed
10 min in methanol at20C. Cells were immunolabelled with Cx37 antibody
(Alpha Diagnostics) as described previously (32). Cells were counterstained
with Evans blue and nuclei were stained with 4#,6-diamidino-2-phenylindole.
Staining was examined with a LSM 510 Meta confocal microscope (Carl Zeiss
AG, Feldbacht, Switzerland) connected to a personal computer, and images
were captured with the software provided by the manufacturer.
siRNA transfection
HeLa cells were transfected with 25 or 50 nM control small interfering RNA
(siRNA) (Control Smart Pool 1; Thermo Scientific Dharmacon, [Lafayette, CO]
or #1108188; Microsynth, Balgach, Switzerland), 25 nM siRNA-GSK-3a (#
s6236; Thermo Scientific Dharmacon) or 50 nM siRNA-GSK-3b (#4390825;
Applied Biosystem-Ambion, Rotkreuz, Switzerland) by using Lipofectamine
RNAiMAX (Invitrogen, Basel, Switzerland). For this purpose, cells were in-
cubated for 48 or 60 h with siRNA. Optimal doses of each siRNA were de-
termined in HeLa cells using different concentrations of siRNA, and the
efficacy of the specific inhibition of GSK-3 isoform expression was evaluated
by western blot by using antibodies against total GSK-3b and total-GSK-3a.
Dye coupling
For analysis of cell-to-cell coupling, one HeLa cell within a cluster was im-
paled with a thin tip microelectrode filled with 1% Lucifer yellow and 2%
neurobiotin solution prepared in 150 mM KCl and buffered to pH 7.2 with
10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid–KOH. The
tracers were allowed to fill the cells by simple diffusion for 3 min (33). Lucifer
yellow was added to the microelectrode solution to visualize and mark the
injected cell. At the end of the injection, the electrode was removed and cells
were fixed with 4% paraformaldehyde. After permeabilization with 0.3% Tri-
ton X-100, neurobiotin diffusion was revealed with streptavidine–rhodamine
(1/3000) for 60 min at room temperature. Fluorescent cells were observed with
an inverted TMD-300 microscope (Nikon, Egg, Switzerland) equipped with
a 40 phase 3 dark medium objective with a numerical aperture of 0.7 (Carl
Zeiss). Images were captured with a Visicam digital camera (Visitron Systems,
Puchheim, Germany) connected to a personal computer running Metafluor
4.01 software (Universal Imaging, Sunnyvale, CA). Numbers of stained cells
were counted.
In a first set of experiments, parental HeLa cells and HeLa cells transfected
with Cx37-319S or Cx37-319P were treated with vehicle (H2O or DMSO) or
GSK-3 inhibitors (10 mM LiCl or 50 lM SB415286) during 15 min before the
microinjection. In a second set of experiments, HeLa cells were transfected
with control siRNA, siRNA-GSK-3b or siRNA-GSK-3a during 48 or 60 h
before the microinjections. Between 6 and 13 injections were performed for
each condition.
Electrical coupling
For electrical coupling studies, the dual whole-cell patch clamp approach was
applied on cell pairs. Patch electrodes were filled with (in mM) 139 KCl,
1 NaCl, 2 MgCl2, 0.5 CaCl2, 5.5 ethyleneglycol-bis(aminoethylether)-
tetraacetic acid, buffered to pH 7.2 with 10 mM N-2-hydroxyethylpiperazine-
N#-2-ethanesulfonic acid–KOH. The external solution was (in mM) 136 NaCl,
4 KCl, 1 CaCl2, 1 MgCl2, 10 N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic
acid and 2.5 glucose (pH 7.4). For some experiments, 10 mM LiCl was added
to the bath solution 15 min before the recording. All experiments were carried
out at room temperature.
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Both cells of a pair were voltage-clamped at a common holding potential of
0 mV using an EPC-9 (HEKA Elektronik, Lambrecht, Germany) and a PC-
501A amplifier (Warner Instruments, Hamden, CT). To measure gap junctional
currents (Ij), transjunctional voltage steps (Vj) of 10 mV were applied. Gap
junctional conductance (gj) was then calculated by gj5 Ij/Vj. Series resistance
was not compensated and was ,2% of the combined junctional and cell input
resistance.
Statistical analysis
The data are presented as mean ± SEM. Independent experiments were com-
pared by Student’s t-test. Differences indicated by an asterisk or a number sign
were considered statistically significant at P , 0.05.
Results
Cx37 expression and cell proliferation in transfected HeLa and
SK-HEP-1 cells
Clones of HeLa transfectants used in this study have been chosen for
their equal expression level of total and membrane Cx37-319S and
Cx37-319P, as described in detail elsewhere (23). To study the effect
of polymorphic Cx37 on HeLa cell growth, cells were cultured during
48 h in 96-well plate. As shown in Figure 1A, Cx37 expression re-
mained similar between HeLa Cx37-319S and Hela Cx37-319P trans-
fectants, the first 2 days after passage during which the proliferation
assays were performed. As shown in Figure 1B (left panel), cell
growth in Cx37-319P-expressing HeLa cells was reduced compared
with clones transfected with EV or with Cx37-319S (P , 0.01). Ex-
pression of Cx37-319S had no effect on HeLa cell growth. Using
short-term (,30 min) adhesion assays, we have shown previously
that mononuclear cells or HeLa cells transfected with Cx37-319P
were less adhesive than cells expressing Cx37-319S due to an in-
creased release of ATP (22,23). To verify that difference in prolifer-
ation between the two cell clones did not result from a difference in
their initial adhesion, we performed another type of proliferation
assay that takes non-adherent cells into account (Figure 1B, right
panel). Whereas we started with an equal number of HeLa cells trans-
fected with Cx37-319S or Cx37-319P after overnight incubation with-
out FBS (T0), we confirmed that Cx37-319P-expressing cells
exhibited reduced growth compared with Cx37-319S-expressing cells
Fig. 1. Cx37 C1019T polymorphism and tumour cell proliferation. (A) Quantification of Cx37 by western blot showed that this protein is equally expressed in
HeLa cells transfected with Cx37-319S and Cx37-319P 24 h (T24) and 48 h (T48) after cell passage. Figure shows representative western blots for Cx37 in
HeLa cells transfected with EV, Cx37-319S (S) or Cx37-319P (P); N 5 7. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used as loading control.
(B) Left panel: cell number measured with crystal violet staining after 48 h in culture for the three HeLa cell transfectants (T48). Results are presented as mean
of seven independent experiments, and each experiment was performed in triplicate. Right panel: cell proliferation measured by the reduction of tetrazolium
compound in the culture medium before (T0) and after 48 h (T48) of proliferation. During the 48 h of proliferation, some cultures were treated with 50 U/ml
apyrase or 200 lM ATP. Results are presented as mean of eight independent experiments, each experiment was performed in triplicate, and results obtained for
HeLa Cx37-319P cells were expressed in fold increase of HeLa Cx37-319S cells. Error bars show SEM, P , 0.01 versus EV and Cx37-319S and P , 0.05
versus Cx37-319S. (C) Left panel: Cx37 western blot of SK-HEP-1 cells transfected with Cx37-319S or Cx37-319P. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) is used as loading control. Right panel: SK-HEP-1 cell proliferation measured by the reduction of tetrazolium compound in the culture medium
before (T0) and after 48 h (T48) of proliferation. Results are presented as mean of six independent experiments, each experiment was performed in triplicate, and
results obtained for SK-HEP-1 Cx37-319P cells were expressed in fold increase of SK-HEP-1 Cx37-319S cells. Error bars show SEM and P , 0.05 versus
Cx37-319S.
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after 48 h of proliferation (T48). Moreover, the differences in growth
between Cx37-319S- and Cx37-319P-expressing cells were main-
tained in the presence of apyrase (an ATP scavenger) or ATP (22),
further indicating that the observed differences in proliferation be-
tween the two clones were probably not caused by differences in cell
adhesion. Finally, the growth-reducing effect of Cx37-319P was con-
firmed in SK-HEP-1 cells, a human endothelial cell line. Indeed, SK-
HEP-1 transfectants expressing similar levels of Cx37-319P and
Cx37-319S displayed a clear difference in proliferation after 48 h
of culturing (T48), whereas the number of cells initially plated (T0)
were equal (Figure 1C). Thus, difference in proliferation between the
two cell clones is not caused by difference adhesion.
Next, we investigated whether the anti-proliferative effect of Cx37-
319P was due to increased cell death, i.e. apoptosis or necrosis. As
shown in the phase-contrast images in Figure 2A, HeLa cells trans-
fected with Cx37-319S, Cx37-319P or EV were all able to grow to
a confluent monolayer of cells. Counting the number of viable and
dead cells present in the supernatant revealed no significant differ-
ences between the three clones. Thus, the number of viable cells (not
stained with Trypan blue) in supernatant was 30 833 ± 6882, 37 500 ±
4743 and 37 917 ± 5568 [N 5 6, not significant (ns)] for Hela EV,
HeLa Cx37-319S and HeLa Cx37-319P, respectively. The number of
dead cells (stained with Trypan blue) in supernatant was 25 000 ±
6090, 54 167 ± 14 034 and 52 500 ± 13 586 (N 5 6, ns) for Hela
EV, HeLa Cx37-319S and HeLa Cx37-319P, respectively. In addition,
no cleaved Caspase-3 was observed in HeLa transfectants after 48 h of
culture (Figure 2B). In contrast, when these HeLa cells were treated with
1 lM staurosporine to induce apoptosis, a 17 kDa band appeared in-
dicative for cleaved Caspase-3 (Figure 2B). Finally, flow cytometry
analysis showed that total cell death was similar between the three
clones when these cells were stained with Annexin V to detect apoptosis
and with 7-aminoactinomycin D to quantify necrosis (Figure 2C). The
percentage of dead cells in the right upper and lower quadrants repre-
sented 12.5 ± 1.2%, 8.2 ± 1.2% and 9.5 ± 2.1% (N5 3, ns) for Hela EV,
HeLa Cx37-319S and HeLa Cx37-319P, respectively.
Predicted phosphorylation site for GSK-3 on Cx37-319S and
Cx37-319P
Cx37 is a phosphoprotein and may display a shift in electrophoretic
mobility on reducing SDS–polyacrylamide gel electrophoresis due to
phosphorylation on serine residues (34). NetPhos analysis of amino
acid sequence of Cx37CT (amino acids 233–333) revealed 10 serine
phosphorylation consensus sequences in Cx37-319S and 9 in Cx37-
319P. Differences involved the region around amino acids 319–321
with the serine at position 319 in Cx37-319S being a putative GSK-3
phosphorylation site. Interestingly, another site for phosphorylation
by GSK-3 was found at amino acid 321 in Cx37-319P only (Table I).
GSK-3 is a Ser/Thr kinase implicated in multiple cellular processes,
Fig. 2. Cell death in HeLa transfectants. (A) Representative photographs of HeLa cells transfected with EV, Cx37-319S and Cx37-319P after 48 h in culture.
All cultures have grown to confluence. (B) Representative western blot for uncleaved and cleaved Caspase-3 in HeLa transfectants. Positive control (Pos. Ctrl.)
was obtained by exposing HeLa cells to 1 lM staurosporine during 24 h. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used as loading control.
(C) Representative Fluorescence Activated Cell Sorting measurements for Annexin V and 7-aminoactinomycin D (7-AAD). The lower left quadrant shows cells
negative for the two staining (viable cells), the lower right quadrant shows cells positive for AnnexinV staining only, representing early apoptosis, and the upper
right quadrant shows cells positive for both Annexin V and 7-AAD representing the dead cell fraction.
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including cell proliferation (reviewed in refs. 27,28). An additional
site for GSK-3 phosphorylation may be found at amino acid 275 in
both Cx37CTs (Table 1). Importantly, action of GSK-3 on a substrate
in living cells requires a priming phosphate at n þ 4 (where n is the
site of phosphorylation for GSK-3) (35,36). This implies that phos-
phorylation on position 275, 319 or 321 by GSK-3 will need a priming
phosphate, respectively, on position 279, 323 or 325. Detailed analysis
of the amino acid sequence of Cx37CT does not show phosphoryla-
tion sites on position 279 or 323 but predicts a serine on position 325
that may be phosphorylated by protein kinase C or ribosomal S6
kinase. Because this priming phosphorylation site is only present in
Cx37CT-319P, one would expect that only this polymorphic isoform
may be phosphorylated by GSK-3 in living cells.
Phosphorylation of Cx37CT by GSK-3b
GSK-3 appears constitutively active in most cells, including HeLa
cells, and becomes inhibited in response to a variety of agonists as
a result of phosphorylation of a single serine residue (Ser9 for GSK-
3b and Ser21 for GSK-3a) (37). Several inhibitors of GSK-3 have
been identified, including lithium ions and SB415286 (37,38). Lith-
ium acts directly by competing with magnesium and also indirectly by
increasing the inhibitory phosphorylation of Ser9 or Ser21 in GSK-3.
SB415286 is a specific inhibitor of GSK-3 that acts by competing with
ATP, which prevents phosphorylation of substrate (39). To study the
effects of GSK-3 on Cx37 phosphorylation, we first determined the
optimal condition for limiting GSK-3 activity in HeLa cells. For this
purpose, we exposed HeLa cells transfected with Cx37-319S, Cx37-
319P or EV to increasing concentrations of the GSK-3 inhibitors LiCl
(0, 5, 10, 20 and 40 mM) or SB415286 (0, 5, 10, 25, 50, 75 and 100 lM)
during 15 min. As shown in Figure 3A, we observed a significant in-
crease in phospho-GSK-3b and phospho-GSK-3a after exposure to
10 mM LiCl. This effect was similar in all three transfectants (data
not shown) and did not further increase with increased concentration of
the substance. A significant decrease in phospho-b-catenin, a substrate
of GSK-3, was already observed after exposure of HeLa transfectants
to 25 lM SB415286 (Figure 3B). Increasing the concentration of
SB415286 up to 100 lM revealed a further dose-dependent decrease
in phospho-b-catenin. However, doses .50 lM have been shown to
exhibit unspecific additional effects (39,40).
As shown in Figure 3C, Cx37CT is phosphorylated by GSK-3b
in vitro. Under basal conditions (reaction in presence of H2O or
DMSO), the phosphorylation statuses of Cx37CT-319S and Cx37CT-
319P are similar. Inhibition of GSK-3b with 10 mM LiCl or 50 lM
SB415286 induced a significant reduction in the phosphorylation of
Cx37CT-319S and Cx37-319P by GSK-3b (P , 0.05). This decrease
of phosphorylation was similar between Cx37CT-319S and Cx37-319P
when GSK-3b was inhibited by LiCl (53 and 58%, respectively, ns), but
enhanced reduction was observed in Cx37CT-319P compared with
Cx37CT-319S using the selective SB415286 inhibitor (65 and 51%,
respectively; P , 0.05). Nevertheless, western blot for Cx37 of HeLa
cells treated with 10 mM LiCl during 15 min did not show a shift in
electrophoretic mobility (data not shown).
GJIC in Cx37-319S and Cx37-319P transfectants in absence or in
presence of GSK-3 inhibitors
Next, we have investigated the subcellular localization of Cx37 in
Cx37-319S- and Cx37-319P-expressing HeLa cells by immunofluores-
cence. As expected for transfected cells, a strong Cx37 immunosignal
was observed perinuclearly in both transfectants and incidentally Cx37
immunosignals were detected at the cell-to-cell interface (Figure 4A).
The specificity of the immunostaining is illustrated by the total absence
of signal in HeLa cells transfected with the EV. The subcellular local-
ization of Cx37 in both Cx37-319S and Cx37-319P transfectants was
not affected by treatment with 10 mM LiCl for 15 min (Figure 4A).
Both Cx37 polymorphic channels formed functional gap junctions as
shown by the extensive cell-to-cell spread of neurobiotin after 3 min of
injection (Figure 4B). In contrast, the parental HeLa cells did not show
diffusion of neurobiotin to neighboring cells (N5 7). Interestingly, the
number of cells labelled with neurobiotin was significantly lower in
HeLa cells expressing Cx37-319P (3.3 ± 0.8) compared with the ones
expressing Cx37-319S (7.7 ± 2.1, P , 0.05; Figure 4B and D). The
difference in GJIC between Cx37-319S- and Cx37-319P-expressing
HeLa cells was not affected by pre-incubation with DMSO, the solvent
of SB415286. Interestingly, inhibition of endogenous GSK-3 activity
by 10 mM LiCl or 50 lM SB415286 significantly increased GJIC
in HeLa cells transfected with Cx37-319P (P , 0.05 versus vehicle),
whereas it did not affect GJIC in Cx37-319S transfectants (Figure 4D)
nor did it affect the absence of coupling in parental HeLa cells (N5 8;
Table I. Predicted phosphorylation sites on the CT of Cx37-319S and Cx37-319P and predicted kinases associated
Cx37CT-319S Cx37CT-319P
a.a. position Predicted a.a. Predicted kinases Score a.a. position Predicted a.a. Predicted kinases Score
254 T — 254 T —
256 S — 256 S —
275 S GSK-3 0 275 S GSK-3 0.53
cdc2 0.58 cdc2 0.58
cdk5 0.66 cdk5 0.66
P38MAPK 0.56 P38MAPK 0.56
285 S CKII 0.56 285 S CKII 0.56
286 S — 286 S —
295 T CKII 0.54 295 T CKII 0.54
cdc2 0.50 cdc2 0.50
302 S PKC 0.54 302 S PKC 0.54
319 S GSK-3 0.51 319 — —
cdk5 0.62
321 S cdc2 0.56 321 S GSK-3 0.52
cdc2 0.53
324 S PKC 0.72 324 S PKC 0.63
325 S PKC 0.71 325 S PKC 0.71
RSK 0.50
328 S PKC 0.86 328 S PKC 0.86
a.a., amino acid; S, serine; T, threonine; cdc2, cell division cycle 2; cdk5, cyclin-dependent kinase 5; MAPK, mitogen-activated protein kinase; CKII, casein kinase
II; PKC, protein kinase C; RSK, ribosomal S6 kinase. Analyses were performed with the NetPhos 2.0 Server and with the NetPhosK 1.0 server. Consensus sites for
GSK-3 are shown in bold.
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data not shown). To specifically determine the effect of each GSK-3
isoform on GJIC in HeLa cells expressing Cx37-319P or Cx37-319S,
we treated these transfectants with siRNA against GSK-3b or GSK-3a
or with control siRNA for 48 or 60 h. The optimal concentration of each
siRNA and the optimal duration of incubation were determined in a
separate experiment (data not shown). As shown in Figure 4C, incuba-
tion with 50 nM GSK-3b siRNA for 48 h specifically decreased the
expression of GSK-3b without affecting the expression of GSK-3a.
Conversely, treatment with 25 nM GSK-3a siRNA for 60 h limited
GSK-3a expression without affecting GSK-3b. The efficacy of each
siRNA was similar between HeLa Cx37-319S cells and HeLa
Cx37-319P cells. We then performed dye injections in HeLa transfec-
tants treated with these different siRNAs. As shown in Figure 4C, de-
creasing the expression of GSK-3b induced a significant increase of the
spread of neurobiotin between Cx37-319P-expressing cells but not
between Cx37-319S-expressing cells. In contrast, decreasing the ex-
pression of GSK-3a did not modify GJIC in HeLa cells transfected with
Cx37-319S or Cx37-319P. Finally, control siRNAwas without effect on
GJIC in both clones.
The cell-to-cell spread of neurobiotin might be influenced by cell
density, we therefore measured electrical coupling between pairs of
cells using the dual whole-cell patch clamp approach. We found that
both HeLa- and SK-HEP-1-transfected cells with Cx37-319S showed
increased gj as compared with Hela or SK-HEP-1 cells expressing
Cx37-319P (Figure 5). Importantly, inhibition of endogenous GSK-3
activity by 10 mM LiCl for 15 min significantly increased gj in cells
transfected with Cx37-319P (P, 0.05), whereas it did not affect gj in
Cx37-319S transfectants (Figure 5).
Fig. 3. Phosphorylation of Cx37CT-319S and Cx37-319P by GSK-3b (A) Representative western blots for phospho-GSK-3b, total-GSK-3b, phospho-GSK-3a,
total-GSK-3a and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (loading control) in HeLa cells treated with different concentrations of LiCl during
15 min. As shown by the quantification of western blots, LiCl increased phosphorylation of GSK-3b and GSK-3a in a dose-dependent manner with a maximal
effect reached at 10 mM; N 5 3. Error bars show SEM and P , 0.05 versus control. (B) Representative western blots for phospho-b-catenin, total-b-catenin
and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (loading control) in HeLa cells treated with different concentrations of SB415286 during 15 min.
As shown by the quantification of western blots, SB415286 decreased phosphorylation of b-catenin, a target for active GSK-3, in a dose-dependent manner, which
reached significance at a dose of 25 lM; N 5 3. Error bars show SEM and P , 0.05 versus control. (C) In basal conditions, GSK-3b phosphorylation of
Cx37CT-319S and Cx37CT-319P is similar. Inhibition of GSK-3b activity by 10 mM LiCl limited phosphorylation of both Cx37 isoforms. However, a higher
efficacy for Cx37CT-319P was observed with 50 lM SB415286 treatment (SB). Data of six or seven independent experiments were expressed in ratio of
phosphorylation status of Cx37CT-319S incubated with H2O. Error bars show SEM,
P, 0.05 versus vehicle and #P, 0.05 versus Cx37CT-319S. Representative
radiographs are shown for each condition.
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Discussion
GJIC has previously been shown to regulate cellular proliferation and
has been implicated in cancer. In a small epidemiological study,
a polymorphism in the human Cx37 gene (C1019T) has been sug-
gested to be associated with susceptibility to angiosarcomas (24).
In the present study, we have compared cell proliferation between
communication-deficient cells (HeLa and SK-HEP-1 cells) stably ex-
pressing similar levels of Cx37-319S and Cx37-319P. Our results
show decreased proliferation of HeLa and SK-HEP-1 cells expressing
Cx37-319P. NetPhos analysis of the CT tail of Cx37 revealed GSK-3
phosphorylation sites in the region around amino acid 319. In vitro
kinase assays, in presence of active recombinant GSK-3b and
Cx37CT-319S or Cx37CT-319P, demonstrated that this GSK-3 was
effectively capable to phosphorylate Cx37CT. We observed reduced
GJIC between Cx37-319P-transfected tumour cells compared with
Fig. 4. Cell-to-cell coupling in HeLa cells expressing Cx37-319S or Cx37-319P. (A) Immunofluorescent staining of HeLa cells transfected with EV, Cx37-319S or
Cx37-319P. Whereas Cx37 was absent in HeLa cells transfected with EV, it was readily detected in HeLa cells transfected with Cx37-319S or Cx37-319P. Cx37
was mainly detected intercellularly in Cx37-319S- or Cx37-319P-expressing cells, and this distribution was not different after LiCl treatment. (B) Intercellular
communication was measured by microinjection of Lucifer yellow and neurobiotin during 3 min. Images are representative examples of neurobiotin diffusion
in HeLa Cx37-319S and Cx37-319P cells submitted or not to treatment with 10 mM LiCl for 15 min before the microinjection. Asterisks indicate the microinjected
cells. (C) Representative western blots of GSK-3b and GSK-3a in HeLa Cx37-319S and HeLa Cx37-319P cells treated with control siRNA, siRNA for
GSK-3b or GSK-3a. GSK-3b siRNA induced a specific decrease of expression of GSK-3b without affecting GSK-3a expression, and GSK-3a siRNA blocked
specifically GSK-3a expression without affecting GSK-3b expression. There was no difference of siRNA efficacy between HeLa Cx37-319S and Cx37-319P cells.
(D) Intercellular communication was measured by microinjection of Lucifer yellow and neurobiotin during 3 min. Inhibition of GSK-3 was induced by adding
10 mM LiCl or 50 lM SB415286 15 min before the microinjections. Alternatively, cells were transfected with siRNA specifically inhibiting GSK-3a or GSK-3b.
In basal conditions, GJIC between Cx37-319P-transfected cells was significantly lower compared with GJIC between Cx37-319S transfectants. Inhibition of
GSK-3 by LiCl or SB415286 (SB) 15 min before the microinjections significantly increased GJIC between Cx37-319P transfectants, whereas GJIC between
Cx37-319S-transfected cells remained unchanged. Specific decrease of GSK-3b expression with siRNA significantly increased GJIC in HeLa Cx37-319P cells but
not in HeLa Cx37-319S cells. Control siRNA and siRNA for GSK-3a did not modify GJIC in the two clones. Results are presented as mean of 6–13
microinjections for each condition. Error bars show SEM and P , 0.05 versus vehicle and #P , 0.05 versus HeLa Cx37-319S cells.
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cells transfected with Cx37-319S. Finally, specific inhibition of GSK-
3b equilibrated cell-to-cell communication in Cx37-319S- and Cx37-
319P-expressing HeLa cells. Overall, our data indicate functional
effects of the Cx37 C1019T polymorphism on GJIC that might con-
tribute to tumour cell growth.
Communication-deficient HeLa cells are commonly used to study
the effects of specific connexins (f.e. Cx43, Cx40, Cx32 or Cx26) on
cellular proliferation (6). Interestingly, expression of Cx43 and Cx26
appeared to decrease cell proliferation, whereas expression of Cx32
and Cx40 was without effect. Recently, Burt et al. (41) have shown
that expression of mouse Cx37 slowed cell cycle progression in com-
munication-deficient rat insulinoma cells. In our models of HeLa and
SK-HEP-1 cells expressing equal amounts of Cx37, Cx37-319S failed
to modify cellular proliferation and Cx37-319P limited it. Thus, the
suppressive action of Cx37 on cell proliferation seems to be specific
for the polymorphic isoform studied.
Because Cx37 is mostly expressed in endothelial cells, its role in
tumour development was first studied in endothelial-derived tumours
such as angiosarcomas. Although Cx37 mutations have been detected
in hepatic angiosarcomas from rats treated with vinyl chloride, they
are probably not crucial for tumour development as they are only rare
events (19). Interestingly, these authors detected Cx37 in endothelial
cells of normal liver, but none of the angiosarcomas showed Cx37
immunoreactivity, suggestive for disturbed Cx37-mediated GJIC in
these tumours. In human, two Cx37 gene polymorphisms have been
studied in relation to cancer. A single-nucleotide polymorphism lead-
ing to an amino acid change (valine-to-isoleucine) at codon 130 in the
cytoplasmic loop of the Cx37 protein showed a similar distribution in
breast and lung cancer patients versus healthy donors (42). However,
genotyping for a second single-nucleotide polymorphism leading to
an amino acid change (proline-to-serine) at codon 319 in the cyto-
plasmic tail of Cx37 revealed the possibility that the Cx37-319S allele
might predispose to vinyl chloride-associated angiosarcoma in human
(24). In agreement with this study, we show that expression of Cx37-
319P limited the proliferation of both HeLa and SK-HEP-1 cells,
tumour cells of epithelial and endothelial origin, whereas the expres-
sion of Cx37-319S was without effect. While the number of samples
in the afore-mentioned epidemiological study (24) was too small to
allow for firm conclusions, it should be noted that most phosphory-
lation sequences reside in Cx37CT and that, in analogy to other con-
nexins (43), changes in phosphorylation state might affect the
function of Cx37, including cell-to-cell communication.
Implications of connexins in tumourigenesis depend on their lo-
calization, their quantity and their phosphorylation status. Various
studies suggest a possible link between kinase activation, connexin
phosphorylation and cell cycle progression (44,45). Importantly,
Larson et al. (34) have demonstrated that Cx37 may be phosphory-
lated on serine, tyrosine or threonine residues; they did not, however,
identify the kinases implicated in this process. In this study, we per-
formed detailed NetPhos analysis on Cx37CT and found that the
region around the polymorphic position 319 may be a site for phos-
phorylation by GSK-3. GSK-3 is a ubiquitous Ser/Thr kinase that was
first described for its role in the phosphorylation and inactivation of
glycogen synthase (46). In mammals, two isoforms of GSK-3 have
been described: GSK-3a and GSK-3b. GSK-3b has been extensively
studied and appeared to be implicated in cellular proliferation and
cancer (reviewed in refs. 27,28). In fact, GSK-3b might act both
as a ‘tumour suppressor’ or as a ‘tumour promoter’ depending on
the organ studied (47). Unlike most protein kinases, GSK-3b is con-
stitutively active in resting cells and .40 proteins have been shown
to be a substrate for GSK-3b. Here, we identify Cx37 as a new sub-
strate for GSK-3b. Using an in vitro kinase assay, we demonstrate
that Cx37CT-319S and Cx37CT-319P are subject to phosphorylation
by GSK-3b. It has been described that a priming phosphorylation at
n þ 4 increases the efficacy of GSK-3 substrate phosphorylation by
100- to 1000-fold in living cells (36,48). Sequence analysis of the
polymorphic Cx37 isoforms showed that only Cx37-319P has a pro-
tein kinase C phosphorylation site at n þ 4 (serine on position 325),
suggesting preferential phosphorylation of this isoform by GSK-3. On
position 275, it seems that a phosphorylation site for GSK-3 could
exist, but the priming phosphorylation site is not present at the posi-
tion 279 suggesting a low efficacy of GSK-3 on this site. Although our
in vitro kinase assays revealed the possibility of GSK-3-dependent
phosphorylation for both Cx37-319P and Cx37-319S when substrate
and kinase were present in excess, inhibition of GSK-3b by the spe-
cific inhibitor SB415286 had a larger effect on phosphorylation effi-
cacy on Cx37CT-319P than on Cx37CT-319S. Unfortunately, it is not
possible to measure the phosphorylation of Cx37 by GSK-3 directly in
cells due to the presence of multiple other kinases predicted to phos-
phorylate Cx37 (Table 1). Therefore, we assume that in living cells
with physiological quantities of Cx37 and GSK-3, GSK-3 will pref-
erentially phosphorylate Cx37-319P.
GSK-3 is an endogenously active kinase in HeLa cells, thus we
expect that Cx37-319P is phosphorylated in our cells under basal
conditions. We observed low cell-to-cell communication, as measured
by neurobiotin diffusion, in HeLa Cx37-319P transfectants compared
with HeLa cells expressing equal amounts of Cx37-319S. Following
inhibition of GSK-3 with LiCl or SB415286, phosphorylation of
Cx37CT-319P decreased and GJIC in HeLa Cx37-319P transfectants
increased. Using isoform specific siRNAs, we showed that limitation
of GSK-3b expression, but not of GSK-3a expression, induced an
increase in GJIC between HeLa Cx37-319P cells. Differences in sub-
strate specificity between the two isoforms of GSK-3 have been de-
scribed before (see ref. for review 47). In general, phosphorylation of
GSK-3 substrates leads to their inactivation (47). Our results are in
accordance with these observations; the phosphorylation of Cx37-
319P by GSK-3 is associated with low Cx37-319P channel function.
In contrast, Cx37-319S channels showed a higher basal GJIC and their
function seemed not affected by GSK-3 inhibitors. It is therefore
likely that, contrary to in vitro kinase assay, GSK-3 does not phos-
phorylate Cx37-319S under physiological conditions or, alternatively,
phosphorylation of Cx37-319S does not affect its gap junction chan-
nel function. In this respect, mutation of the priming Ser325 site in
Cx37-319P might help to obtain further insight in post-translational
modifications of Cx37CT in link to its function. Finally, it has been
recently demonstrated that 24 h treatment of skeletal myoblasts with
LiCl modified Cx43 expression and gap junctional communication
Fig. 5. Gap junctional conductance in cells expressing Cx37-319S or
Cx37-319P. Gap junctional conductance (gj) was measured by dual
whole-cell patch clamp on HeLa or SK-HEP-1 cells pairs stably expressing
similar amount of Cx37-319P or Cx37-319S. Inhibition of GSK-3 was
induced by adding 10 mM LiCl 15 min before the recordings. In basal
conditions, gj between Cx37-319P-transfected cells was significantly lower
compared with gj between Cx37-319S transfectants. Inhibition of GSK-3 by
LiCl significantly increased gj between Cx37-319P transfectants whereas
gj between Cx37-319S-transfected cells remained unchanged. Because HeLa
and SK-HEP-1 transfectants showed similar behaviour, gj values were pooled
for graphic presentation. Under control conditions, N 5 4 for HeLa
Cx37-319P and N 5 4 for SK-HEP-1-Cx37-319P and N 5 3 for HeLa
Cx37-319S and N 5 4 for SK-HEP-1-Cx37-319S. In the presence of LiCl,
N5 7 for HeLa Cx37-319P and N5 4 SK-HEP-1-Cx37-319P and N5 4 for
HeLa Cx37-319S and N 5 2 for SK-HEP-1-Cx37-319S.
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(49,50). This long-term regulation of Cx43 expression by LiCl
seemed to involve the Wnt signaling pathway, affecting both the
transcription and phosphorylation of the protein. Together with our
data, these studies show that GSK-3 is important for the regulation of
connexins at multiple levels, varying from transcription and expres-
sion to channel function.
The first observations linking gap junction function and cell growth
control have been described 40 years ago. Since then, a tremendous
amount of evidence has shown that connexins are somehow linked to
cell proliferation and cancer, but the mechanism is far from being
resolved (see ref. for review 7). More recent studies have demon-
strated that Cx43-mediated GJIC may modify gene expression of
cancer cells by selectively permitting the passage of some intracellu-
lar metabolites (51,52). In our study, only the expression of Cx37-
319P limited proliferation in HeLa cells and SK-HEP-1 cells. The
differences in anti-proliferative properties between Cx37-319S and
Cx37-319P might be due to different channel selectivity for gene
expression-regulating metabolites between these cells.
In conclusion, our results suggest that GSK-3b by maintaining
Cx37-319P endogenously in a phosphorylated state limits GJIC and
reduces proliferation of multiple types of tumour cells. These results
support the tumour suppressor role of GSK-3b and Cx37. Moreover,
they underline the importance for large epidemiological studies towards
a possible association between the Cx37 C1019T polymorphism and
the development of endothelial-derived tumours.
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